journal
MENU ▼
Read by QxMD icon Read
search

Therapeutic Advances in Psychopharmacology

journal
https://www.readbyqxmd.com/read/29607005/the-antipsychotic-landscape-dopamine-and-beyond
#1
REVIEW
Paul D Morrison, Robin M Murray
Until recently, the actions of antipsychotic and pro-psychotic drugs have largely been evaluated in the framework of neuronal doctrine - namely, that neurons communicate by releasing transmitters, and that psychiatric disorders are caused by neurotransmitter imbalances. Moreover, the majority of studies have focused on single transmitter systems - neglecting the fact that in the nervous system, different transmitter systems work in concert and impact on not only their immediate receptors but also downstream pathways that shape structural plasticity...
April 2018: Therapeutic Advances in Psychopharmacology
https://www.readbyqxmd.com/read/29607004/a-prospective-year-long-follow-up-of-lurasidone-use-in-clinical-practice-factors-predicting-treatment-persistence
#2
Ian J Osborne, Shubhra Mace, David Taylor
Background: Our aim was to follow up patients prescribed lurasidone over 1 year to determine factors predicting treatment persistence. Methods: We used noninterventional, observational, prospective follow up of patients consecutively prescribed lurasidone in a large inner-city NHS mental health trust. We also performed retrospective analysis of outcomes from patient case notes. Results: Data were available for 69 patients consecutively prescribed lurasidone, of whom three (4%) were lost to follow up...
April 2018: Therapeutic Advances in Psychopharmacology
https://www.readbyqxmd.com/read/29492258/benzodiazepine-prescription-in-ontario-residents-aged-65-and-over-a-population-based-study-from-1998-to-2013
#3
Simon J C Davies, Binu Jacob, David Rudoler, Juveria Zaheer, Claire de Oliveira, Paul Kurdyak
Background: Although commonly used in anxiety and insomnia, recent guidelines recommend caution when prescribing benzodiazepines in the elderly. Here we examined rates of benzodiazepine prescribing to older adults in Ontario, Canada from 1998 to 2013 and impact of legislation that made prescribing regulations more strict. Method: Annual benzodiazepine prescription rates for Ontario residents aged 65 and over were examined using the Ontario Drug Benefit database which captures all publicly funded prescriptions...
March 2018: Therapeutic Advances in Psychopharmacology
https://www.readbyqxmd.com/read/29492257/alternatives-to-ketamine-in-depression-state-of-the-art-and-future-perspectives
#4
EDITORIAL
Luke A Jelen, Sinead King, James M Stone
No abstract text is available yet for this article.
March 2018: Therapeutic Advances in Psychopharmacology
https://www.readbyqxmd.com/read/29399320/neuromodulation-for-the-treatment-of-eating-disorders-and-obesity
#5
REVIEW
Darrin J Lee, Gavin J B Elias, Andres M Lozano
Eating disorders and obesity adversely affect individuals both medically and psychologically, leading to reduced life expectancy and poor quality of life. While there exist a number of treatments for anorexia, morbid obesity and bulimia, many patients do not respond favorably to current behavioral, medical or bariatric surgical management. Neuromodulation has been postulated as a potential treatment for eating disorders and obesity. In particular, deep brain stimulation and transcranial non-invasive brain stimulation have been studied for these indications across a variety of brain targets...
February 2018: Therapeutic Advances in Psychopharmacology
https://www.readbyqxmd.com/read/29344345/when-the-drugs-don-t-work-treatment-resistant-schizophrenia-serotonin-and-serendipity
#6
Penelope Lowe, Amir Krivoy, Lilla Porffy, Erna Henriksdottir, Whiskey Eromona, Sukhwinder S Shergill
Treatment-resistant schizophrenia is a serious clinical problem. We adopt a systems-level approach positing a greater role for cognitive control mechanisms in the development of psychotic symptoms and illustrate the clinical application of this via a case report of treatment-resistant patients treated successfully with adjunct pro-cognitive serotonergic medication.
January 2018: Therapeutic Advances in Psychopharmacology
https://www.readbyqxmd.com/read/29344344/acetylcholinesterase-inhibitors-in-treatment-resistant-psychotic-depression
#7
Chris Smart, Hamish McAllister-Williams, David Andrew Cousins
Dopamine receptor antagonists can be effective in psychotic depression but response is not assured. Visual hallucinations may arise from a dysregulation of brain cholinergic systems and acetylcholinesterase inhibitors (AChEIs) can treat such hallucinations in dementia with Lewy bodies (DLB). AChEIs have been used in schizophrenia with some success but their efficacy and tolerability in psychotic depression is unclear. This striking case illustrates AChEIs specifically targeting multimodal hallucinations in treatment-resistant depression...
January 2018: Therapeutic Advances in Psychopharmacology
https://www.readbyqxmd.com/read/29344343/the-role-of-selective-serotonin-reuptake-inhibitors-in-preventing-relapse-of-major-depressive-disorder
#8
REVIEW
Steven S Clevenger, Devvrat Malhotra, Jonathan Dang, Brigitte Vanle, Waguih William IsHak
The objective of this review was to evaluate the efficacy of selective serotonin reuptake inhibitors (SSRIs) and SSRIs compared with other treatment modalities in preventing relapse after an episode of major depressive disorder (MDD). An Ovid MEDLINE and PsycINFO search (from 1987 to August 2017) was conducted using the following terms: selective serotonin reuptake inhibitors, antidepressants, depression, prevention, prophylaxis, relapse and MDD. Using predefined criteria, two authors independently selected and reached consensus on the included studies...
January 2018: Therapeutic Advances in Psychopharmacology
https://www.readbyqxmd.com/read/29344342/frontotemporal-dementia-latest-evidence-and-clinical-implications
#9
REVIEW
Juan Joseph Young, Mallika Lavakumar, Deena Tampi, Silpa Balachandran, Rajesh R Tampi
Background: Frontotemporal dementia (FTD) describes a cluster of neurocognitive syndromes that present with impairment of executive functioning, changes in behavior, and a decrease in language proficiency. FTD is the second most common form of dementia in those younger than 65 years and is expected to increase in prevalence as the population ages. This goal in our review is to describe advances in the understanding of neurobiological pathology, classification, assessment, and treatment of FTD syndromes...
January 2018: Therapeutic Advances in Psychopharmacology
https://www.readbyqxmd.com/read/29344341/treatment-of-adult-adhd-a-clinical-perspective
#10
REVIEW
Josh Geffen, Kieran Forster
Adult attention deficit/hyperactivity disorder (ADHD) has moved from the blurred edge of clinical focus to clear recognition as a prevalent and significant disorder in its own right. It is a relatively common comorbidity which if identified and treated may open the door to better outcomes for hard-to-treat patients. Conversely, failure to identify and treat adult ADHD is linked to negative outcomes. The recognition of the importance of adult ADHD in a subset of our patients challenges us to overcome our anxiety about this diagnosis and prevent the societal marginalization of vulnerable patients...
January 2018: Therapeutic Advances in Psychopharmacology
https://www.readbyqxmd.com/read/29344340/assessment-and-management-of-sexual-dysfunction-in-the-context-of-depression
#11
REVIEW
Pratap R Chokka, Jeffrey R Hankey
Sexual dysfunction (SD) is pervasive and underreported, and its effects on quality of life are underestimated. Due in part to its bidirectional relationship with depression, SD can be difficult to diagnose; it is also a common side effect of many antidepressants, leading to treatment noncompliance. While physicians often count on patients to spontaneously report SD, treatment is optimized when the clinician instead performs a thorough assessment of sexual functioning before and during drug therapy using a standardized questionnaire such as the Arizona Sexual Experiences Scale (ASEX)...
January 2018: Therapeutic Advances in Psychopharmacology
https://www.readbyqxmd.com/read/29344339/clozapine-discontinuation-in-early-schizophrenia-a-retrospective-case-note-review-of-patients-under-an-early-intervention-service
#12
Andrew Shaker, Rowena Jones
Aim: Research in patients with treatment-resistant schizophrenia has demonstrated that clozapine discontinuation is associated with poor outcomes. There is, however, a paucity of research investigating the impact of clozapine discontinuation specifically in younger patients with more recent onset schizophrenia. A case note review was therefore conducted to ascertain medium-term prognoses in patients with treatment-resistant schizophrenia under an early intervention service (EIS) following clozapine discontinuation...
January 2018: Therapeutic Advances in Psychopharmacology
https://www.readbyqxmd.com/read/29201344/combinations-of-qtc-prolonging-drugs-towards-disentangling-pharmacokinetic-and-pharmacodynamic-effects-in-their-potentially-additive-nature
#13
Andreas D Meid, Irene Bighelli, Sarah Mächler, Gerd Mikus, Giuseppe Carrà, Mariasole Castellazzi, Claudio Lucii, Giovanni Martinotti, Michela Nosè, Giovanni Ostuzzi, Corrado Barbui, Walter E Haefeli
Background: Whether arrhythmia risks will increase if drugs with electrocardiographic (ECG) QT-prolonging properties are combined is generally supposed but not well studied. Based on available evidence, the Arizona Center for Education and Research on Therapeutics (AZCERT) classification defines the risk of QT prolongation for exposure to single drugs. We aimed to investigate how combining AZCERT drug categories impacts QT duration and how relative drug exposure affects the extent of pharmacodynamic drug-drug interactions...
December 2017: Therapeutic Advances in Psychopharmacology
https://www.readbyqxmd.com/read/29090087/extended-release-methylphenidate-monotherapy-in-patients-with-comorbid-social-anxiety-disorder-and-adult-attention-deficit-hyperactivity-disorder-retrospective-case-series
#14
Ahmet Koyuncu, Fahri Çelebi, Erhan Ertekin, Burcu Ece Kök, Raşit Tükel
BACKGROUND: The relationship between social anxiety disorder (SAD) and attention-deficit/hyperactivity disorder (ADHD) is a subject which has recently become a topic of interest for research. METHODS: In this study, 20 patients with comorbid SAD and adult ADHD who were treated with extended-release methylphenidate monotherapy were evaluated retrospectively. RESULTS: Clinical response for both ADHD and SAD symptoms was observed in 17 of 20 patients...
November 2017: Therapeutic Advances in Psychopharmacology
https://www.readbyqxmd.com/read/29090086/the-prospects-of-cariprazine-in-the-treatment-of-schizophrenia
#15
EDITORIAL
Jonathan R Scarff
No abstract text is available yet for this article.
November 2017: Therapeutic Advances in Psychopharmacology
https://www.readbyqxmd.com/read/28966787/a-stitch-in-time-3-monthly-long-acting-injectable-paliperidone-palmitate-in-schizophrenia
#16
EDITORIAL
Mark Taylor, Hannah Chu-Han Huang
No abstract text is available yet for this article.
October 2017: Therapeutic Advances in Psychopharmacology
https://www.readbyqxmd.com/read/28966786/urgent-release-of-severe-psychomotor-retardation-with-intramuscular-lorazepam-a-case-report
#17
Mark Kanzawa, Beena Premkumar
No abstract text is available yet for this article.
October 2017: Therapeutic Advances in Psychopharmacology
https://www.readbyqxmd.com/read/28959434/naltrexone-efficacy-in-treating-alcohol-use-disorder-in-individuals-with-comorbid-psychosis-a-systematic-review
#18
REVIEW
Martyna Sawicka, Derek K Tracy
BACKGROUND: Psychotic illnesses, such as schizophrenia, are typically enduring and disabling conditions, impacting individual, family, and societal outcomes. Individuals with these face greater vulnerabilities in developing alcohol-use disorder (AUD). Furthermore, the nature of psychoses, often manifesting with paranoia, cognitive impairment, a lack of insight, sub-optimal treatment adherence, and stigma from others, means that they can pose unique treatment challenges when these two conditions comorbidly occur...
September 2017: Therapeutic Advances in Psychopharmacology
https://www.readbyqxmd.com/read/28959433/clozapine-induced-hypersalivation-the-association-between-quantification-perceived-burden-and-treatment-satisfaction-reported-by-patients
#19
Wai Hong Man, Jantine Colen-de Koning, Peter Schulte, Wiepke Cahn, Ingrid van Haelst, Eibert Heerdink, Ingeborg Wilting
No abstract text is available yet for this article.
September 2017: Therapeutic Advances in Psychopharmacology
https://www.readbyqxmd.com/read/28740637/antipsychotic-induced-hyperprolactinemia-in-tourette-syndrome
#20
REVIEW
Judith J G Rath, Marlies E J Deen, Hessel van Houten, Sebastiaan F T M de Bruijn, Joop van Gerven, Dick Mul
For many years, Tourette syndrome (TS) was considered to be a rare disorder, but tics and TS are now recognized as fairly common childhood-onset conditions. Children and adolescents with TS are frequently treated with antipsychotics, either as monotherapy or in combination with psychostimulants, melatonin and selective serotonin reuptake inhibitors (SSRIs). Antipsychotics are most often used in schizophrenia and related psychotic disorders, and in these conditions hyperprolactinemia is one of the most common adverse effects associated with antipsychotics, occurring in 40-50% of patients...
July 2017: Therapeutic Advances in Psychopharmacology
journal
journal
43489
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"